Adaptimmune Revenue and Competitors

Abingdon, USA



Total Funding



Estimated Revenue & Valuation

  • Adaptimmune's estimated annual revenue is currently $6.2M per year.(i)
  • Adaptimmune received $Undisclosed in venture funding in March 2017.
  • Adaptimmune's estimated revenue per employee is $13,543
  • Adaptimmune's total funding is $399.5M.
  • Adaptimmune's current valuation is $515.5M. (January 2022)

Employee Data

  • Adaptimmune has 460 Employees.(i)
  • Adaptimmune grew their employee count by -15% last year.

Adaptimmune's People

Chief Operating OffcerReveal Email/Phone
Sr. VP, Late Stage DevelopmentReveal Email/Phone
CEOReveal Email/Phone
VP, Translational SciencesReveal Email/Phone
VP, Head Global Regulatory AffairsReveal Email/Phone
SVP Early Stage DevelopmentReveal Email/Phone
Head, Global Supplier QualityReveal Email/Phone
VP and Head, Global Sourcing & ProcurementReveal Email/Phone
SVP, General CounselReveal Email/Phone
VP Corporate Strategy & OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Adaptimmune?

Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit If interested in joining our fast growing team, click on the careers tab of this page.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Adaptimmune News

2022-04-20 - Why Adaptimmune Therapeutics, Agenus, and Sorrento ...

A premium-rich buyout is sparking a rally among experimental cancer companies today. Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics...

2022-04-13 - Why Adaptimmune Therapeutics Shares Dropped 14.7% on ...

Adaptimmune Therapeutics focuses on T- cell therapies to fight cancer. It has big plans for its therapy to treat a rare soft-tissue cancer.

2022-04-13 - Adaptimmune Presents MAGE-A4 Expression Data from its ...

Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors.

2021-02-13 - An­oth­er Keytru­da com­bo tops stan­dard of care in ad­vanced kid­ney can­cer, pos­ing new test for Bris­tol's I/O med

It makes sense to join forces with your partner’s owner. Japan’s Astellas Pharma is tying up with UK-based Adaptimmune Therapeutics in a deal worth up to $897.5 million to develop stem-cell-derived, off-the-shelf T-cell therapies. Since 2015, Adaptimmune has been collaborating with a Seattle ba ...

2015-05-07 - Bill and Melinda Gates Foundation putting $75M toward disease surveillance, Roche gets FDA approval for venetoclax (Morning Read)

LIFE SCIENCE Adaptimmune, a UK-based biotech using T-cell therapy to treat cancer and infectious disease, raised $191 million in its IPO. The company priced 11.3 million shares at the high end of the range ($17 per share) for a market cap of $1.3 billion, according to Fortune. But it wavered in ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Adaptimmune Funding

DateAmountRoundLead InvestorsReference